Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

This study provides valuable real-world evidence that confirms the long-term efficacy of pembrolizumab outside of clinical trials. Hierarchical organization indicates ECOG-PS, age and PD-L1-TPS as the most important predictors of 5-year survival, potentially informing clinical practice.

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2025-02-01
DOI
https://doi.org/10.1136/jitc-2024-010674
Citations
15
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
15.68

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

Andrea Napolitano, Francesco Passiglia, David James Pinato, Martin Sebastian et al.
15 citations
Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and Biomarkers
15.68
article

Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry

Andrea Napolitano, Francesco Passiglia, David James Pinato, Martin Sebastian, Lauren Young, Mieke Van Hemelrijck, Michele Ghidini, Gabriele Minuti, Rita Barros, Ritujith Jayakrishnan, Bartłomiej Tomasik, Francesco Pantano, Alessandro Russo, Federica Pecci, Edoardo Garbo, Laura Mezquita, Isabelle Monnet, Valter Torri, Diego Signorelli, Joachim G.J.V. Aerts, Raffaele Giusti, Monica Verrico, Anne‐Marie C. Dingemans, So Yeon Kim, Francesco Agustoni, Rita Chiari, Francesca Mazzoni, Marianna Macerelli, Talal El Zarif, Artur Katz, Biagio Ricciuti, Emilio Bria, Francesco Grossi, Kazuki Takada, Joel W. Neal, Eleni Karapanagiotou, Giulio Metro, Maximilian Rost, Paolo Bironzo, Alessandra Curioni‐Fontecedro, Thomas Newsom-Davis, Mary J. Fidler, Sukumar Kalvapudi, Giannis Mountzios, Jarushka Naidoo, Michele De Tursi, Mingjia Li, Laura Moliner, Leonardo Brunetti, Alessandro Morabito, Chiara Bennati, Michele Montrone, Annalisa Guida, Uma Mukherjee, Diego Cortinovis, Marco Russano, Giuseppina Rita Di Fazio, Alex Friedlaender, Federica Zoratto, Elisa Roca, Margarita Majem, Giuseppe Tonini, Andrea Camerini, Alessio Cortellini, Luca Cantini, David O’Reilly, Alberto Servetto, Solange Peters, Lorenza Maria Landi, Alfredo Addeo, Javier Baena Preysler, Sai Yendamuri, Alessandro Leonetti, Scott Gettinger, Alessandro Di Federico, Federica Biello, Alessandro Inno, Eleni Josephides, Bruno Vincenzi, Teresa Gorría, Taher Abu Hejleh, Martin Förster, Luigi Della Gravara, Andrea De Giglio, Avinash Aujayeb, Frank Aboubakar Nana, Madeleine Dupont, Joao V. Alessi, Giuseppe Lo Russo, Alain Gelibter, Armida D’Incecco, Carlo Genova, Mark M. Awad, Jacobo Rogado, Teresa Beninato, Abdul Rafeh Naqash, Dwight Hall Owen, Nichola Awosika, Roberto Ferrara, Salvatore Grisanti, Matthew J. Loza, Marina Chiara Garassino, Heather Wakelee, Gianpaolo Spinelli, Jack S. Bell, Claudia A M Fulgenzi
article en
15 citations

Abstract

This study provides valuable real-world evidence that confirms the long-term efficacy of pembrolizumab outside of clinical trials. Hierarchical organization indicates ECOG-PS, age and PD-L1-TPS as the most important predictors of 5-year survival, potentially informing clinical practice.

Journal for ImmunoTherapy of CancerVol. 13(2)
Università Cattolica del Sacro Cuore (IT), Goethe University Frankfurt (DE), University of Insubria (IT), Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), University of Teramo (IT), University of Parma (IT), University of Iowa (US), Rush University Medical Center (US), Roswell Park Comprehensive Cancer Center (US), Albert Einstein College of Medicine (US), Cliniques Universitaires Saint-Luc (BE), St Thomas' Hospital (GB), Royal Marsden NHS Foundation Trust (GB), Montefiore Medical Center (US), University College London Hospitals NHS Foundation Trust (GB), Johns Hopkins University (US), University of Fribourg (CH), Vita-Salute San Raffaele University (IT), Università Campus Bio-Medico (IT), King's College London (GB), Mario Negri Institute for Pharmacological Research (IT), King Hussein Cancer Center (JO), Policlinico Umberto I (IT), Northumbria Healthcare NHS Foundation Trust (GB), Hammersmith Hospital (GB), Hospital de Sant Pau (ES), Beaumont Hospital (IE), Centre Hospitalier Universitaire Vaudois (CH), Agostino Gemelli University Polyclinic (IT), Yale Cancer Center (US), University of Oklahoma Medical Center (US), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), University of Chieti-Pescara (IT), University of Chicago (US), Azienda Ospedaliera di Perugia (IT), Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT), Hospital Universitario 12 De Octubre (ES), Ospedale Sacro Cuore Don Calabria (IT), University Hospital of Geneva (CH), Institut Català d'Oncologia (ES), Azienda Unità Sanitaria Locale Della Romagna (IT), Azienda Ospedaliera San Gerardo (IT), Hospital Clínic de Barcelona (ES), Azienda Ospedaliero-Universitaria Careggi (IT), CTO Andrea Alesini (IT), Dana-Farber Cancer Institute (US), Azienda Ospedaliera S.Maria (IT), Ospedale Santa Maria della Misericordia di Udine (IT), Istituto Tumori Bari (IT), University Hospital Frankfurt (DE), IRCCS Ospedale San Raffaele (IT), Chelsea and Westminster Hospital (GB), Ospedale Santa Maria Goretti (IT), Ospedale Monaldi (IT), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Campus Bio Medico University Hospital (IT), Ospedale Policlinico San Martino (IT), Saiseikai Fukuoka General Hospital (JP), Hospital Sírio-Libanês (BR), Erasmus MC Cancer Institute (NL), Policlinico San Matteo Fondazione (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Henry Dunant Hospital (GR), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Ospedale Versilia (IT), Hôpital Intercommunal de Créteil (FR), Générale-Beaulieu Clinic (CH), Sidney Kimmel Comprehensive Cancer Center (US), Hospital Universitario Infanta Leonor (ES), University College London (GB), Imperial College London (GB), The Ohio State University (US), University of Turin (IT), University of Milano-Bicocca (IT), University of Naples Federico II (IT), Gdańsk Medical University (PL), University of Brescia (IT), Sapienza University of Rome (IT), University of Bologna (IT), Stanford University (US)
International Association for the Study of Lung Cancer, Ministero della Salute, Associazione Italiana per la Ricerca sul Cancro, Università Cattolica del Sacro Cuore
Partnerships for the goals
Openalex Percentile: Top 1%
Cancer Immunotherapy and Biomarkers
15.68
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.